November 5, 2013
Pharmaceutical group Shire PLC said Vyvanse, its amphetamine-based drug prescribed to U.S. students to control ADHD, had also been successful in treating the newly-recognized binge eating disorder (BED) in a trial.
Shares in the London-listed firm rose to an all-time high on Tuesday after it said the drug was superior to a placebo in reducing the number of binge-eating days per week in two randomized late-stage trials.
It said it would submit an application to the U.S. drugs regulator, the FDA, for the approval of the drug for BED after the results of the tests, which were completed earlier than expected.
Shire’s chief executive Flemming Ornskov, who joined the company earlier this year, said he was extremely pleased with the results.
This article was posted: Tuesday, November 5, 2013 at 5:41 am